A selection of ongoing Phase III trials investigating combination therapies or new BCG strains in BCG Naïve NMIBC patients.
| NCT03528694 | AstraZeneca | Imfinzi | PD-L1 Inhibitor | Phase III | Yes | 1 | Oct, 2024 |
|---|---|---|---|---|---|---|---|
| NCT04165317 | Pfizer | Sasanlimab | PD-L1 Inhibitor | Phase III | Yes | 1,070 | Jun, 2024 |
| NCT03799835 | Roche | Atezolizumab | PD-L1 Inhibitor | Phase III | Yes | 500 | Apr, 2024 |
| NCT03711032 | Merck | Keytruda | PD-L1 Inhibitor | Phase III | Yes | 1,400 | Dec, 2025 |
| NCT02948543 | University of Sydney | Mitomycin | Antineoplastic antibiotic | Phase III | Yes | 501 | Dec, 2024 |
| NCT03091660 | NCI and SWOG | Tokyo-172 | BCG strain | Phase III | No | 1,000 | Dec, 2024 |